BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29786784)

  • 1. Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.
    Lam HM; Nguyen HM; Corey E
    Methods Mol Biol; 2018; 1786():1-27. PubMed ID: 29786784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
    Philp LK
    Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
    Lawrence MG; Obinata D; Sandhu S; Selth LA; Wong SQ; Porter LH; Lister N; Pook D; Pezaro CJ; Goode DL; Rebello RJ; Clark AK; Papargiris M; Van Gramberg J; Hanson AR; Banks P; Wang H; Niranjan B; Keerthikumar S; Hedwards S; Huglo A; Yang R; Henzler C; Li Y; Lopez-Campos F; Castro E; Toivanen R; Azad A; Bolton D; Goad J; Grummet J; Harewood L; Kourambas J; Lawrentschuk N; Moon D; Murphy DG; Sengupta S; Snow R; Thorne H; Mitchell C; Pedersen J; Clouston D; Norden S; Ryan A; Dehm SM; Tilley WD; Pearson RB; Hannan RD; Frydenberg M; Furic L; Taylor RA; Risbridger GP
    Eur Urol; 2018 Nov; 74(5):562-572. PubMed ID: 30049486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of patient-derived xenografts in prostate cancer research.
    Lawrence MG; Taylor RA; Cuffe GB; Ang LS; Clark AK; Goode DL; Porter LH; Le Magnen C; Navone NM; Schalken JA; Wang Y; van Weerden WM; Corey E; Isaacs JT; Nelson PS; Risbridger GP
    Nat Rev Urol; 2023 Jun; 20(6):371-384. PubMed ID: 36650259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
    Risbridger GP; Clark AK; Porter LH; Toivanen R; Bakshi A; Lister NL; Pook D; Pezaro CJ; Sandhu S; Keerthikumar S; Quezada Urban R; Papargiris M; Kraska J; Madsen HB; Wang H; Richards MG; Niranjan B; O'Dea S; Teng L; Wheelahan W; Li Z; Choo N; Ouyang JF; Thorne H; Devereux L; Hicks RJ; Sengupta S; Harewood L; Iddawala M; Azad AA; Goad J; Grummet J; Kourambas J; Kwan EM; Moon D; Murphy DG; Pedersen J; Clouston D; Norden S; Ryan A; Furic L; Goode DL; Frydenberg M; Lawrence MG; Taylor RA
    Nat Commun; 2021 Aug; 12(1):5049. PubMed ID: 34413304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
    Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
    Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
    Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
    Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
    Porter LH; Lawrence MG; Wang H; Clark AK; Bakshi A; Obinata D; Goode D; Papargiris M; Mural ; Clouston D; Ryan A; Norden S; Corey E; Nelson PS; Isaacs JT; Grummet J; Kourambas J; Sandhu S; Murphy DG; Pook D; Frydenberg M; Taylor RA; Risbridger GP
    Prostate; 2019 Aug; 79(11):1326-1337. PubMed ID: 31212368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
    Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
    Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.
    Lin D; Wyatt AW; Xue H; Wang Y; Dong X; Haegert A; Wu R; Brahmbhatt S; Mo F; Jong L; Bell RH; Anderson S; Hurtado-Coll A; Fazli L; Sharma M; Beltran H; Rubin M; Cox M; Gout PW; Morris J; Goldenberg L; Volik SV; Gleave ME; Collins CC; Wang Y
    Cancer Res; 2014 Feb; 74(4):1272-83. PubMed ID: 24356420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
    Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
    Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
    Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
    Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.
    Lawrence MG; Pook DW; Wang H; Porter LH; Frydenberg M; Kourambas J; Appu S; Poole C; Beardsley EK; Ryan A; Norden S; Papargiris MM; Risbridger GP; Taylor RA
    Prostate; 2015 Sep; 75(13):1475-83. PubMed ID: 26177841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient derived organoids to model rare prostate cancer phenotypes.
    Puca L; Bareja R; Prandi D; Shaw R; Benelli M; Karthaus WR; Hess J; Sigouros M; Donoghue A; Kossai M; Gao D; Cyrta J; Sailer V; Vosoughi A; Pauli C; Churakova Y; Cheung C; Deonarine LD; McNary TJ; Rosati R; Tagawa ST; Nanus DM; Mosquera JM; Sawyers CL; Chen Y; Inghirami G; Rao RA; Grandori C; Elemento O; Sboner A; Demichelis F; Rubin MA; Beltran H
    Nat Commun; 2018 Jun; 9(1):2404. PubMed ID: 29921838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived xenografts (PDXs) as model systems for human cancer.
    Invrea F; Rovito R; Torchiaro E; Petti C; Isella C; Medico E
    Curr Opin Biotechnol; 2020 Jun; 63():151-156. PubMed ID: 32070860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
    Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.